Detalhe da pesquisa
1.
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Invest New Drugs
; 40(1): 115-123, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34515877
2.
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Breast Cancer Res Treat
; 188(2): 477-487, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852121
3.
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
Pancreatology
; 20(1): 101-109, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31787526
4.
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Gynecol Oncol
; 146(1): 64-68, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28461031
5.
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
BMC Cancer
; 16(1): 814, 2016 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27765027
6.
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.
Gynecol Oncol
; 141(2): 348-356, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26946093
7.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Gynecol Oncol
; 143(2): 379-388, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27614696
8.
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Cancer
; 120(12): 1890-7, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24619793
9.
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Gynecol Oncol
; 134(3): 478-85, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25016924
10.
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
Breast Cancer Res Treat
; 139(1): 145-53, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23605083
11.
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
Invest New Drugs
; 30(5): 1934-41, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21881915
12.
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Gynecol Oncol
; 124(2): 210-5, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22047770
13.
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Invest New Drugs
; 29(3): 473-80, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20082116
14.
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Gynecol Oncol
; 122(1): 116-20, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21514634
15.
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Lancet Oncol
; 11(2): 129-35, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20036194
16.
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
Sci Rep
; 11(1): 8076, 2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33850213
17.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ Breast Cancer
; 7(1): 131, 2021 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611148
18.
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
NAR Cancer
; 3(3): zcab028, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34316715
19.
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
Clin Cancer Res
; 26(20): 5329-5337, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816943
20.
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Theranostics
; 10(5): 2095-2114, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32104500